4
letter from the ceo
LETTER FROM JOHAN LÖF, CEO AND FOUNDER
INNOVATION, COLLABORATION, ADAPTATION Against the backdrop of COVID-19 and ongoing societal and economic disruption, RaySearch has doubled down on the fundamentals: innovative new products, continuous improvement of existing software, and clinical partnerships that inform our technology and commercial strategy. Throughout 2021 we continue to embrace our necessarily modified ways of working and collaborating while moving forward with cautious optimism to deliver our vision for comprehensive cancer care. GROWTH THROUGH DIVERSIFICATION Despite the operational impact of the pandemic, the RaySearch development teams registered impressive progress along multiple fronts in 2020. We ended the year with the launch of two high-profile new products – RayIntelligence® and RayCommand®* – both of which underpin significant diversification of our software portfolio.
As our “engine-room” for data-driven oncology and machine learning, RayIntelligence provides a cloud-based analytics system to inform the planning, optimization and management of cutting-edge cancer treatments. This softwareas-a-service (SaaS) platform integrates seamlessly with our RayStation* treatment planning system (TPS) and RayCare* oncology information system (OIS), enabling cancer clinics to consolidate, structure and interrogate their fragmented data stores to individualize treatment protocols * Subject to regulatory clearance in some markets.
and enhance patient outcomes. There are tools for deep analysis of trends and performance; dashboards for an at-aglance overview of clinical activities; while the structured data enables clinics to define datasets that are suitable for training machine learning models. RayIntelligence is a departure in other ways as well, with an annual subscription license model that allows customers to spread their software investment over an extended timeframe. Elsewhere, the focus is on hardware integration. The RayCommand treatment control system (TCS) offers unified management and control of key systems in the radiotherapy treatment room – the treatment machine, treatment couch, imaging systems and patient positioning devices. The goal: to ensure safe and effective patient care while offering a more consistent user experience and enhanced workflow efficiency – regardless of the type of treatment machine. As such, we see this B2B product as a catalyst for innovation and increased competition in the radiotherapy equipment market, encouraging new-entrant system vendors to integrate RayCommand rather than developing their own TCS from scratch. KEEP EVOLVING, KEEP IMPROVING The evolution of our core software products also continued at pace last year. New versions of RayStation (10A and 10B) added support for high-dose-rate brachytherapy planning and proton therapy planning for the treatment of eye cancer. Equally significant, the latest iteration of the software’s Monte Carlo dose calculation engine is already shaping up as a game-changer for planning workflows at proton therapy
